medigraphic.com

2005, Number 5

<< Back Next >>

Cir Cir 2005; 73 (5)

Sensitivity, specificity and predictive values of the level of hemoglobin, haematocrit and platelet count as an activity index in ulcerative colitis

Ibarra-Rodríguez JJ, Santiago-Luna E, Velázquez-Ramírez GA, López-Ramírez MKL, Fuentes-Orozco C, Cortés-Flores AO, González-Ojeda A

Language: Spanish
References: 38
Page: 355-362
PDF size: 231.89 Kb.


ABSTRACT

Introduction: Ulcerative colitis (UC) is a disease characterized by relapsing and remitting non-infectious inflammation of the colorectal mucosa. Its heterogeneity makes assessment of the disease’s activity a prerequisite for a rational choice of therapy. We aimed to determine sensitivity, specificity, positive and negative predictive values of hemoglobin, hematocrit and platelets to develop a simplified activity index of UC.
Material and methods: Sixty patients with UC were included and submitted to measurements of hemoglobin, hematocrit and platelets, as well as sigmoidoscopy and biopsy. Sensitivity and specificity, positive and negative predictive values were correlated with the reported degree of activity in the biopsy. Kruskal-Wallis test was used to determine differences between groups, and Pearson and Spearman rank tests were used to correlate each parameter with the degree of activity. A p value ‹ 0.05 was considered statistically significant.
Results: Moderate (n = 15), severe (n = 15) and normal histology as a control group (n = 15). Thirty four (57 %) were female and 26 (43 %) male. Average age was 26 ± 12.8 years. Sensitivity and specificity for hemoglobin level was 51 and 100 %, respectively, 51 and 100 % for hematocrit, and 84 and 100 % for platelet counts.
Spearman’s correlation for hemoglobin was r = –0.866 (p ‹ 0.001), for hematocrit r = –0.864 (p ‹ 0.001) and for platelets r = 0.928 (p ‹ 0.001).
Conclusions: Hemoglobin and hematocrit are useful to catalogue the degree of activity of UC when it is severe. Platelet count may be a marker of severity at any time, due to its high sensitivity and specificity as a diagnostic test.


REFERENCES

  1. Ghosh S, Shand A, Fergunson A. Ulcerative colitis. Br Med J 2000;320:1119-1123.

  2. Podolsky DK. Medical progress: inflammatory bowel disease. N Engl J Med 2002; 347:417-429.

  3. Ardizzone S, Bianchi P. Inflammatory bowel disease: new insights into pathogenesis and treatment. J Intern Med 2002;252:475-496.

  4. Nagura H, Matsumoto T. Immunopathology of inflammatory bowel disease. Pathol Case Rev 2002;7:247-253.

  5. Cross R, Wilson K. Nitric oxide in inflammatory bowel disease. Inflamm Bowel Dis 2003;9:179-189.

  6. Geboes K, Riddell R, Öst A, Jensfelt B, Persson T, Löfberg R. A reproducible grading scale for histological assessment of inflammation in ulcerative colitis. Gut 2000;47(3):404-409.

  7. Dan K, Inokuchi K. Effects of interleukin-1 and tumor necrosis factor on megakaryocytopoiesis: mechanism of reactive thrombocytosis. Acta Haematol 1995;93:67-70.

  8. Kaser A, Brandacher G, Steurer W, et al. Interleukin-6 stimulates thrombopoiesis through thrombopoietin: role in inflammatory thrombocytosis. Blood 2001;98:2720-2725.

  9. Carole E, David S. Platelet dysfunction: a new dimension in inflammatory bowel disease. Gut 1995;36(1):5-8.

  10. Danese S, De la Motte C, Fiochi C. Platelets and inflammatory bowel disease. Clinical, pathogenic and therapeutic implications. Am J Gastroenterol 2004;99:938-945.

  11. Feng L, Sutherland L. Assessing disease activity and disease activity indices for inflammatory bowel disease. Curr Gastroenterol Rep 2002;4:490-496.

  12. Friedman S. Current Diagnosis and Treatment in Gastroenterology, 2nd ed. New York: McGraw-Hill;2003. pp. 121-127.

  13. Rizzello F, Gionchetti P, Venturi A, Amandini C, Romagnoli R, Campieri M. Monitoring activity in ulcerative colitis. Aliment Pharmacol Therap 2002;16(suppl 1.4):3-6.

  14. Walmsley R, Ayres R, Pounder R, Allan N. A simple clinical colitis activity index. Gut 1998;43(1):29-32.

  15. Moum B, Ekbom A, Vatn M, et al. Change in the extent of colonoscopic and histological involvement in ulcerative colitis over time. Am J Gastroenterol 1999;94:1564-1569.

  16. Niv Y, Bat L, Ron E, et al. Change in the extent of colonic involvement in ulcerative colitis: a colonoscopic study. Am J Gastroenterol 1987;82:1046-1055.

  17. Tanaka M, Masuda T, Takashi Y, et al. Observer variation of diagnosis based on simple biopsy criteria differentiating among Crohn’s disease, ulcerative colitis, and other forms of colitis. J Gastroenterol Hepatol 2001;16:1368-1372.

  18. Escher J, Kate F, Lichtenbelt K, et al. Value of rectosigmoidoscopy with biopsies for diagnosis of inflammatory bowel disease in children. Inflamm Bowel Dis 2002;8:16-22.

  19. Truelove S, Witts LJ. Cortisone in ulcerative colitis: final report on a therapeutic trial. Br Med J 1955;2:1041-1048.

  20. Morowitz DA, Allen LW, Kirsner JB. Thrombocytosis in chronic inflammatory bowel disease. Ann Intern Med 1968;68:1013-1021.

  21. Talstad I, Rootwelt K, Gjone E. Thrombocytosis in ulcerative colitis and Crohn’s disease. Scand J Gastroenterol 1973;8:135-138.

  22. Harries AD, Fitzsimons E, Fifield R, et al. Platelet count: a simple measure of activity in Crohn’s disease. Br Med J 1983;286:1476.

  23. Harries AD, Beeching NJ, Rogerson SJ, et al. The platelet count as a simple measure to distinguish inflammatory bowel disease from infective diarrhea. J Infect 1991;22:247-250.

  24. Jaremo P, Dandberg-Gertzen H. Platelet density and size in inflammatory bowel disease. Thromb Haesmost 1996;75:560-561.

  25. Kapsoritakis AN, Koukourakis MI, Sfiridaki A, Potamianos SP, Kosmadaki MG, Koutroubakis IE, Kouroumalis EA. Mean platelet volume: a useful marker of inflammatory bowel disease activity. Am J Gastroenterol 2001;96:776-781.

  26. Bernstein CN, Blanchard JF, Houston DS, Wadja A. The incidence of deep venous thrombosis and pulmonary embolism among patients with inflammatory bowel disease. A population based-cohort study. Thromb Haemost 2001;85:430-434.

  27. Collins CE, Cahill MR, Newland AC, et al. Platelets circulate in an activated state in inflammatory bowel disease. Gastroenterology 1994;106:840-845.

  28. Collins CE, Rampton DS, Rogers J, et al. Platelet aggregation and neutrophil sequestration in the mesenteric circulation in inflammatory bowel disease. Eur J Gastroenterol Hepatol 1997;9:1213-1217.

  29. Danese S, de La Motte C, Sturm A, et al. Platelets trigger a CD40-dependent inflammatory response in the microvasculature of inflammatory bowel disease patients. Gastroenterology 2003;124:1249-1264.

  30. Danese S, Katz J, Saibeni S, et al. Activated platelets are the source of elevated levels of soluble CD40 ligand in the circulation of inflammatory bowel disease patients. Gut 2003;52:1435-1441.

  31. Mannaioni PF, Di Bello MG, Masini E. Platelets and inflammation: role of platelet-derived growth factor, adhesion molecules and histamine. Inflamm Res 1997;46:4-18.

  32. Salgado R, Benoy I, Bogers J, et al. Platelet and vascular endotelial growth factor (VEGF): a morphological and functional study. Angiogenesis 2001;4:37-43.

  33. Power CA, Clemetson JM, Clemetson KJ, et al. Chemokine and chemokine receptor mRNA expression in human platelets. Cytokine 1995;7:479-482.

  34. Lindemann S, Tolley ND, Dixon DA, et al. Activated platelets mediate inflammatory signaling by regulated interleukin 1 beta synthesis. J Cell Biol 2001;154:485-490.

  35. Damas JK, Waehre T, Yndestad A, et al. Interleukin-7 mediated inflammation in unstable angina. Possible role of chemokines and platelets. Circulation 2003;107:2670-2676.

  36. Schafer AI. Current concepts: thrombocytosis. N Engl J Med 2004;

  37. 350:1211-1219.

  38. Cabrera-Abreu JC, Davies P, Matek Z, Murphy MS. Performance of blood tests in diagnosis of inflammatory bowel disease in a specialist clinic. Arch Dis Child 2004;89:69-71.




2020     |     www.medigraphic.com